Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase (BTK) that has revolutionized treatment of chronic lymphocytic leukemia (CLL) and is FDA approved for several hematologic indications (9). The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.